Nabriva Therapeutics AG (NBRV)
(Delayed Data from NSDQ)
$2.16 USD
+0.01 (0.47%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.16 USD
+0.01 (0.47%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study
by Zacks Equity Research
Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.
All You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to Buy
by Zacks Equity Research
Nabriva Therapeutics AG (NBRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
uniQure (QURE) Moves 5% Higher: Will This Strength Last?
by Zacks Equity Research
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nabriva Therapeutics AG (NBRV) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Nabriva Therapeutics AG (NBRV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down 25.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Nabriva Therapeutics AG (NBRV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Nabriva Therapeutics (NBRV) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Nabriva Therapeutics (NBRV) has been struggling lately, but the selling pressure may be coming to an end soon.
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in first-quarter fiscal 2022.
Down 15.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV)
by Zacks Equity Research
Nabriva Therapeutics AG (NBRV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
bluebird (BLUE) Q1 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
bluebird (BLUE) reports a wider-than-expected loss for the first quarter of 2021 while revenues beat estimates.
Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q1 revenues increase year over year. The company is progressing well with its pipeline. The company launches its third DMD drug, Vyondys 53, in quarter.
Arena (ARNA) Q1 Earnings Beat Estimates, Etrasimod Progresses
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats Q1 bottom-line estimates. The company progresses with the development of its key pipeline candidate, etrasimod.
Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) beats earnings and revenue estimates in the first quarter. Stock gains 1.7%.
Global Blood's (GBT) Q1 Earnings Miss, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports a wider-than-expected loss in the first quarter of 2021 and its revenues also miss estimates.
Horizon's (HZNP) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Horizon (HZNP) misses estimates for earnings in the first quarter of 2021 while revenues beat the same.
ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates
by Zacks Equity Research
ACADIA's (ACAD) loss narrows in the first quarter of 2021 while its revenues miss the mark. Robust Nuplazid performance drives the top line year over year.
Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the first quarter due to the ongoing pandemic.
Editas (EDIT) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Editas (EDIT) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Pipeline development remains in focus for the company.
Ultragenyx (RARE) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical (RARE) Q1 sales increase year over year while loss narrows
Repligen (RGEN) Beats on Q1 Earnings & Sales, Raises 2021 View
by Zacks Equity Research
Repligen (RGEN) reports encouraging first-quarter results with sales and earnings beating estimates. The company also raises its guidance for 2021. Stock up.
Alexion (ALXN) Tops Q1 Earnings, Merger With AstraZeneca On Track
by Zacks Equity Research
Alexion (ALXN) tops earnings and sales in the first quarter of 2021. Its merger with AstraZeneca is expected to close in the third quarter.
BioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide Decision
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and revenues in the first quarter of 2021.
Blueprint Medicines (BPMC) Q1 Earnings Beat, Revenues Lag
by Zacks Equity Research
Blueprint Medicines' (BPMC) beat estimates for earnings in the first quarter of 2021 while revenues miss the same.
Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress
by Zacks Equity Research
Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.
Vertex (VRTX) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Vertex (VRTX) beats both earnings and sales estimates in Q1 and keeps product sales outlook for 2021.
Apellis' (APLS) Q1 Earnings Miss, Pegcetacoplan in Focus
by Zacks Equity Research
Apellis' (APLS) earnings lag estimates in the first quarter of 2021. Main focus of the company is on its lead pipeline candidate, pegcetacoplan.